Antimicrobial

Appili Therapeutics Announces Additional Bridge Loan from  Bloom Burton & Co.Appili Therapeutics Announces Additional Bridge Loan from  Bloom Burton & Co.

Appili Therapeutics Announces Additional Bridge Loan from Bloom Burton & Co.

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES HALIFAX, Nova Scotia, April 26,…

1 year ago
Orchard Software Announces New Electronic Support for Antimicrobial StewardshipOrchard Software Announces New Electronic Support for Antimicrobial Stewardship

Orchard Software Announces New Electronic Support for Antimicrobial Stewardship

CARMEL, Ind., April 25, 2024 /PRNewswire/ -- Today, Orchard Software announced the availability of interface support for Antimicrobial Use and…

1 year ago
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patientsSNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase…

1 year ago
SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patientsSNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients

SNIPR Biome receives funding from CARB-X to support advancement of CRISPR-medicine SNIPR001 into clinical trials in haematological cancer patients Phase…

1 year ago
Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)

Recce Pharmaceuticals Completes 5,000 RECCE® 327 Doses a Week under Good Manufacturing Practice (GMP)

Successful production of 5,000 x RECCE® 327 (R327) doses per week under Good Manufacturing Practises (GMP) campaignR327 manufactured under GMP…

1 year ago
CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America ConferenceCorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference

CorMedix Inc. Announces Abstracts at Upcoming Society for Healthcare Epidemiology of America Conference

BERKELEY HEIGHTS, N.J., April 11, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic…

1 year ago
CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLCCorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC

CorMedix Inc. Announces Commercial Agreement With ARC Dialysis, LLC

BERKELEY HEIGHTS, N.J., April 08, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing therapeutic…

1 year ago
HD Nursing and WellnessMats Announce Strategic Partnership, Improving Comfort and Safety of Healthcare Professionals with Medical Grade Premium Standing SolutionsHD Nursing and WellnessMats Announce Strategic Partnership, Improving Comfort and Safety of Healthcare Professionals with Medical Grade Premium Standing Solutions

HD Nursing and WellnessMats Announce Strategic Partnership, Improving Comfort and Safety of Healthcare Professionals with Medical Grade Premium Standing Solutions

BENTON, Ark. & TROY, Mich.--(BUSINESS WIRE)--HD Nursing, the leading patient safety solution that combines predictive analytics with individualized fall and…

1 year ago